-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, researchers at the Cleveland Clinic in the United States will start a phase I vaccine trial, which may also become the first ever vaccine to prevent triple-negative breast cancer
The decision to advance the trial was made after the U.
Although triple-negative breast cancer only occurs in about 10% to 15% of breast cancer cases, this type of breast cancer has a high mortality and recurrence rate
In the previous 20 years of research, researchers have confirmed in animal studies that training the patient’s immune system to target cells that produce alpha-lactalbumin can inhibit the growth of breast tumors and even stop the breast from the beginning.
It is worth noting that this phase I test was funded by the US Department of Defense
The Phase I breast cancer research conducted this time is also based on the preclinical research done by Dr.
In addition to targeting α-lactalbumin, the industry is also studying other potential vaccine mechanisms to prevent breast cancer, including PLGA particle vaccine Riboxxim and GP2 vaccine
GP2 is a transmembrane peptide containing 9 amino acids, derived from the HER2/neu protein, which is expressed in 75% of breast cancers and other common cancers
Reference source: Trial For World's First Potential Breast Cancer Vaccine Begins
